Moderna meets forecast with $18.4 billion in COVID vaccine sales in 2022
Jan 9 (Reuters) - Moderna Inc (MRNA.O) said on Monday it generated about $18.4 billion in COVID-19 vaccine sales in 2022, meeting its forecast of $18 billion-$19 billion for the year.
The company also forecast minimum COVID-19 vaccine sales of about $5 billion in 2023, compared with its previous forecast of $4.5 billion to $5.5 billion in November.
The COVID vaccine maker continues to expect additional contracts for 2023, it said.
Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.